The overall survival (OS) time, recurrence-free survival (RFS) time, progression-free survival (PFS) time and disease-specific survival (DSS) time of HCC patients with low METTL14 expression are shorter than those of patients with high METTL14 expression [78]. This evidence concerns the gene METTL14 and hepatocellular carcinoma.